drugset / Trial / NCT03505554
A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to define the objective response rates (ORR) of Lorlatinib in subjects with ALK+ lymphomas resistant or refractory to ALK inhibitors.
Timeline
- Start
- 2019-09-28
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lorlatinib | Small molecule | 100 mg | Oral |